Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients

Mahesh Kudrimoti, Amarinthia Curtis, Samar Azawi, Francis Worden, Sanford Katz, Douglas Adkins, Marcelo Bonomi, Zack Scott, Jenna Elder, Stephen T. Sonis, Richard Straube, Oreola Donini

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Innate immunity is a key component in the pathogenesis of oral mucositis, a universal toxicity of chemoradiation therapy (CRT). Dusquetide, a novel Innate Defense Regulator, has demonstrated both nonclinical and clinical efficacy in ameliorating severe oral mucositis (SOM). Long term follow-up studies from the Phase 2 clinical study evaluating dusquetide as a treatment for SOM in head and neck cancer (HNC) patients receiving CRT have now been completed. Extended analysis indicates that dusquetide therapy was well-tolerated and did not contribute to increased infection, tumor growth or mortality. Potential ancillary benefits of duquetide therapy were also identified.

Original languageEnglish
Pages (from-to)24-26
Number of pages3
JournalBiotechnology Reports
Volume15
DOIs
StatePublished - Sep 2017

Keywords

  • Cancer supportive care
  • Dusquetide
  • Head and neck cancer
  • Immune
  • Innate
  • Oral mucositis

Fingerprint Dive into the research topics of 'Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients'. Together they form a unique fingerprint.

  • Cite this

    Kudrimoti, M., Curtis, A., Azawi, S., Worden, F., Katz, S., Adkins, D., Bonomi, M., Scott, Z., Elder, J., Sonis, S. T., Straube, R., & Donini, O. (2017). Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients. Biotechnology Reports, 15, 24-26. https://doi.org/10.1016/j.btre.2017.05.002